Ulcerative Colitis

Examining recent developments in ASUC management, including predictive markers for colectomy, new treatment approaches, and ongoing challenges.

Topline results from the phase 2b ANTHEM-UC study show all 3 doses of once-daily oral icotrokinra met the primary endpoint for clinical response.

The gastroenterology month in review spotlights GI FDA news, research about colorectal cancer and alcohol complications, and new data for mirikizumab.

Amneal Pharmaceuticals launched mesalamine 800 mg delayed-release tablets for UC and received FDA approval for various lenalidomide doses for blood cancers.

Future intensified intra-class competition among Omvoh, Skyrizi and Tremfya is expected as each brand attempts differentiation.

The sBLA seeks to expand golimumab’s approval for UC to include pediatric patients ≥ 2 years of age and is supported by data from the PURSUIT program.

Positive phase 2b data show duvakitug met primary endpoints for clinical remission in ulcerative colitis and endoscopic response in Crohn disease.

This month in review spotlights GI pipeline updates and news from the 2024 NASPGHAN and ACG annual meetings.

Post hoc analyses from the LIBERTY trials support infliximab as either a monotherapy or combination therapy for ulcerative colitis or Crohn's disease.

The decision is based on rates of clinical and endoscopic remission with guselkumab in the ongoing phase 2b/3 QUASAR study.

The July 2024 gastroenterology month in review highlights FDA news, GI pipeline updates, and a new clinical practice update from the American Gastroenterological Assocation.

Data from INSPIRE and COMMAND were used to support risankizumab’s FDA approval for ulcerative colitis, demonstrating the IL-23 inhibitor’s impact on clinical remission.

The June 2024 gastroenterology month in review highlights FDA news and other pipeline developments in GI as well as the publication of the latest installment of Qazi Corner.

Findings from a post hoc analysis of True North and its open-label extension highlight ozanimod’s rapid onset of action and durability in advanced therapy-naive patients with UC.

The approval is based on data from a pair of phase 3 studies and makes risankizumab-rzaa the first IL-23 specific inhibitor approved for both ulcerative colitis and Crohn’s disease.

Findings suggest cuffitis after ileal pouch-anal anastomosis is linked to long-term complications including strictures and fistulas, potentially contributing to a greater risk of pouch failure.

In honor of World Digestive Health Day, this feature examines the growth of intestinal ultrasound in IBD care in the US and how it aligns with STRIDE-II guidance.

The phase 3 QUASAR Maintenance study met its primary endpoint of clinical remission and demonstrated statistically significant endoscopic remission rates in UC treatment.